Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of (Deficit) Equity

v3.19.3.a.u2
Consolidated Statements of (Deficit) Equity - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Noncontrolling Interest [Member]
Series B Preferred Stock [Member]
Total
Balance at Dec. 31, 2017 $ 4 $ 192,670 $ (194,170) $ (1,914) $ 0 $ (3,410)
Balance (in shares) at Dec. 31, 2017 3,671,014       0  
Stock-based compensation $ 0 2,074 0 0 $ 0 2,074
Stock issued under "at-the-market" offering $ 3 12,169 0 0 0 12,172
Stock issued under "at-the-market" offering (in shares) 3,534,982          
Common stock and warrants issued to vendors $ 0 35 0 0 0 35
Common stock and warrants issued to vendors (in Shares) 50,000          
Series A Preferred Stock Dividends $ 0 0 (243) 0 $ 0 (243)
Stock issued for exercise of stock options (in shares)         0  
Series B preferred stock beneficial conversion feature discount 0 0 (9,161) 0 $ 9,161 0
Issuance of Common Stock, preferred Stock and Warrants in Units Offering, net of issuance costs $ 2 16,273 0 0 $ 641 16,916
Issuance of Common Stock, preferred Stock and Warrants in Units Offering, net of issuance costs (in shares) 2,520,000       15,723  
Issuance of SYN Biomics Stock $ 0 977 0 (941) $ 0 36
Conversion of Series B Preferred Stock to Common $ 6 6,556 (2,520) 0 $ (4,042) 0
Conversion of Series B Preferred Stock to Common (in shares) 5,706,087       (6,562)  
Net loss $ 0 0 (13,367) 0 $ 0 (13,367)
Non-controlling interest 0 0 0 (54) 0 (54)
Balance at Dec. 31, 2018 $ 15 230,754 (219,461) (2,909) $ 5,760 14,159
Balance (in shares) at Dec. 31, 2018 15,482,083       9,161  
Stock-based compensation $ 0 340 0 0 $ 0 340
Series A Preferred Stock Dividends 0 0 (248) 0 0 (248)
Issuance of SYN Biomics Stock 0 (36) 0 108 0 72
Conversion of Series B Preferred Stock to Common $ 2 1,522 (525) 0 $ (999) 0
Conversion of Series B Preferred Stock to Common (in shares) 1,324,347       (1,523)  
Net loss $ 0 0 (15,303) 0 $ 0 (15,303)
Non-controlling interest 0 0 0 (77) 0 (77)
Balance at Dec. 31, 2019 $ 17 $ 232,580 $ (235,537) $ (2,878) $ 4,761 $ (1,057)
Balance (in shares) at Dec. 31, 2019 16,806,430       7,638